SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· CIK 0001061983

CYTK

CYTOKINETICS INC
$64.69 ▼ -1.41%
Prev close $65.62
Market cap$9.2B
ConsensusStrong Buy
12-mo target$109.90 (+69.9%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)40 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CYTK right now — valuation, ownership and activity at a glance.
Market Cap
$9.2B
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (89%)
Inst. Holders
50 funds
Inst. Value
$9.4B
Inst. Activity
40 buys / 10 sells
Insider Activity
$0.00 buy / $16.1M sell
Insider Net $
-$16.1M
SEC Reports
20
Press Releases
7
Congressional
1 trades
Price chart 30d -10.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Nov 14, 2026 fda_pdufa
PDUFA: CYTK — aficamten in obstructive hypertrophic cardiomyopathy — 2026-11-14
FDA target action date 2026-11-14 for CYTK (CYTOKINETICS INC). Drug: aficamten. Indication: obstruct
Sep 28, 2026 Insider
Blum Robert I acquired via exercise 7,500 shares
President & CEO @ $10.60 ($79.5K)
Sep 28, 2026 Insider
Blum Robert I sold 7,500 shares
President & CEO @ $65.46 ($490.9K)
Sep 22, 2026 Insider
Malik Fady Ibraham acquired via exercise 3,500 shares
EVP Research & Development @ $7.80 ($27.3K)
Sep 16, 2026 SEC
Cytokinetics CEO Robert Blum sold $7.3M in open-market shares (97,926 shares at $69.33 and 7,500 at $73.44) alongside di
CLUSTER — Impact 5/10
Sep 11, 2026 SEC
Two insiders at Cytokinetics sold a combined $339K in open-market sales over a week. The EVP of R&D exercised and immedi
CLUSTER — Impact 2/10
Sep 2, 2026 SEC
Three CYTK insiders (CEO, EVP, Director) sold a total of $1.59M in open-market shares over a 7-day window, primarily fro
CLUSTER — Impact 2/10
Aug 29, 2026 Press
Cytokinetics presented positive additional Phase 3 results at ESC 2026 showing aficamten (MYQORZO) improves cardiac stru
Impact 7/10
Analyst ratings buy % +4.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 89% rate it Buy or better · 28 analysts
Strong Buy 6 21% Buy 19 68% Hold 3 11% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Aug 31, 2026HC Wainwright & Co.REITERATEBuy 43%
Aug 13, 2026BarclaysMAINTAINOverweight 54%
Aug 13, 2026JP MorganMAINTAINOverweight 55%
Aug 10, 2026Truist SecuritiesMAINTAINBuy 55%
Aug 7, 2026RBC CapitalMAINTAINOutperform 55%
Aug 7, 2026CitizensMAINTAINMarket Outperform 38%
Aug 7, 2026NeedhamMAINTAINBuy 50%
Jul 7, 2026RBC CapitalMAINTAINOutperform 55%
Jun 29, 2026UBSUPGRADEBuy 55%
Jun 24, 2026MizuhoMAINTAINOutperform 52%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202661930089%
Aug 1, 202661930089%
Jul 1, 202661930089%
Jun 1, 202661840086%
May 1, 202651840085%
Apr 1, 202651740085%
Mar 1, 202651740085%
Feb 1, 202651740085%
Price targets
Where 20 covering analysts think CYTK trades over the next 12 months.
$109.90 +69.9% upside Strong Buy
Current$64.70 Low$85.00 Median$107.50 High$146.00 20 analysts
$85.00$146.00
Analyst rating Strong Buy· 1.5/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 1 bullish, 1 bearish, 2 mixed, 16 neutral · avg impact 3.0/10.Plus 7 press releases.
BEARISHCLUSTER5/10
Cytokinetics CEO Robert Blum sold $7.3M in open-market shares (97,926 shares at $69.33 and 7,500 at
Sep 16, 2026
NEUTRALCLUSTER2/10
Two insiders at Cytokinetics sold a combined $339K in open-market sales over a week. The EVP of R&D
Sep 11, 2026
NEUTRALCLUSTER2/10
Three CYTK insiders (CEO, EVP, Director) sold a total of $1.59M in open-market shares over a 7-day w
Sep 2, 2026
NEUTRALCLUSTER3/10
CEO Robert Blum and EVP Andrew Callos each exercised and immediately sold vested stock options on th
Aug 31, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Nov 14, 2026
fda_pdufa
PDUFA: CYTK — aficamten in obstructive hypertrophic cardiomyopathy — 2026-11-14
FDA target action date 2026-11-14 for CYTK (CYTOKINETICS INC). Drug: aficamten. Indication: obstructive hypertrophic cardiomyopathy. sNDA for aficamte
Oct 2, 2026
other
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations,
Oct 1, 2026
short_volume
Short Volume: CYTK — 58.6% short (0.4M / 0.7M)
Short: 432,306 | Exempt: 0 | TRF Vol: 737,698 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
other
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Pract
Sep 29, 2026
short_volume
Short Volume: CYTK — 79.4% short (0.8M / 1.0M)
Short: 802,630 | Exempt: 286 | TRF Vol: 1,011,204 | Short Ratio: 79.4% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-1.43$-1.65–$-1.107.2%+0.8%11↑ 3↓$0.0B16
Next Q$-1.41$-1.76–$-1.026.2%-0.1%11↑ 3↓$0.1B16
Current FY$-5.94$-6.38–$-4.759.1%+0.1%14↑ 1↓$0.1B16
Next FY$-4.45$-5.90–$-3.1425.1%-0.3%10↑ 3↓$0.4B16
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-1.431—
7d ago$-1.431—
30d ago$-1.443+0.012
60d ago$-1.547+0.117
90d ago$-1.589+0.159
Institutional ownership
Which big funds own CYTK (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $9.4B total value (110,043,901 shares) as of 2026-Q2. Top holders: NOMURA, BlackRock,, WELLINGTON. Net buying activity: 40 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
NOMURA ASSET MANAGEMENT CO LTD0$0.000.0%—
BlackRock, Inc.20,094,362$1.7B18.3%—
WELLINGTON MANAGEMENT GROUP LLP6,931,770$590.5M6.3%—
VANGUARD PORTFOLIO MANAGEMENT LLC6,711,799$571.8M6.1%—
STATE STREET CORP6,494,233$553.2M5.9%—
VANGUARD CAPITAL MANAGEMENT LLC6,117,515$521.2M5.6%—
FMR LLC5,031,782$428.7M4.6%TRIM -53.1%
Avoro Capital Advisors LLC4,999,999$425.9M4.5%ADD +50.0%
BANK OF AMERICA CORP /DE/4,635,709$394.9M4.2%ADD +48.3%
GEODE CAPITAL MANAGEMENT, LLC3,712,501$316.3M3.4%—
Recent position changes
FundActionPrevCurrentChangeValue
FMR LLCTRIM10,723,1405,031,782-53.1%$428.7M
Avoro Capital Advisors LLCADD3,333,3334,999,999+50.0%$425.9M
BANK OF AMERICA CORP /DE/ADD3,125,4364,635,709+48.3%$394.9M
Polar Capital Holdings PlcADD1,661,2482,253,649+35.7%$192.0M
Capital Research Global InvestorsDOUBLED770,9991,686,625+118.8%$143.7M
JPMORGAN CHASE & COADD903,8051,588,895+75.8%$139.2M
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCADD1,087,5911,603,442+47.4%$136.6M
Point72 Asset Management, L.P.DOUBLED626,1021,587,712+153.6%$135.3M
SUSQUEHANNA INTERNATIONAL GROUP, LLPADD898,9511,549,458+72.4%$132.0M
UBS Group AGTRIM2,077,2771,171,287-43.6%$99.8M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$16.1M — $0.00 bought, $16.1M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 28, 2026Blum Robert IPresident & CEOEXERCISE7,500$10.60$79.5K
Sep 28, 2026Blum Robert IPresident & CEOSELL7,500$65.46$490.9K
Sep 22, 2026Malik Fady IbrahamEVP Research & DevelopmentEXERCISE3,500$7.80$27.3K
Sep 22, 2026Malik Fady IbrahamEVP Research & DevelopmentSELL3,500$68.29$239.0K
Sep 15, 2026Blum Robert IPresident & CEOSELL97,926$69.33$6.8M
Sep 15, 2026Landry Robert EDirectorSELL1,000$72.13$72.1K
Sep 14, 2026Blum Robert IPresident & CEOEXERCISE7,500$10.60$79.5K
Sep 14, 2026Blum Robert IPresident & CEOGIFT97,926——
Sep 14, 2026Blum Robert IPresident & CEOGIFT1,350——
Sep 14, 2026Blum Robert IPresident & CEOSELL7,500$73.44$550.8K
Congressional trades
CYTK trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
DateMemberPartyChamberTypeAmountAssetDisclosed
Jun 30, 2026Gilbert CisnerosDHOUSEBUY$1,001 - $15,000CYTOKINETICS INCJul 3, 2026(4d)
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CYTK.
Shares short
17,481,383
Settlement Sep 15, 2026
Change vs prior
+0.2%
Semi-monthly cycle
Days to cover
10.6
At avg daily volume
Of shares outstanding
≈12.6%
Estimate — not % of float
All CYTK filing & press-release reports (32)